BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 15606339)

  • 1. [Cetuximab. A monoclonal antibody against the EGF receptor].
    Wasielewski S
    Med Monatsschr Pharm; 2004 Sep; 27(9):292-4. PubMed ID: 15490614
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
    Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
    Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results].
    Adenis A; Hebbar M
    Bull Cancer; 2005 Aug; 92(Spec no):S21-8. PubMed ID: 16387666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab: from biology to the care of colorectal cancer patients.
    Vincenzi B; Santini D; Tonini G
    Future Oncol; 2007 Oct; 3(5):497-9. PubMed ID: 17927513
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in the treatment of colorectal cancer.
    Veronese ML; O'Dwyer PJ
    Eur J Cancer; 2004 Jun; 40(9):1292-301. PubMed ID: 15177487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab, its clinical use and future perspectives.
    Rivera F; Vega-Villegas ME; López-Brea MF
    Anticancer Drugs; 2008 Feb; 19(2):99-113. PubMed ID: 18176106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cetuximab (Erbitux)].
    Shimoyama T
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1203-12. PubMed ID: 19620819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A; Crombet T; González G
    Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family.
    Sartor CI
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):15-20; discussion 92-100. PubMed ID: 11236022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.
    Trivin F; Boucher E; Raoul JL
    Acta Oncol; 2004; 43(6):592-3. PubMed ID: 15370619
    [No Abstract]   [Full Text] [Related]  

  • 17. Signaling multiplex of the epidermal growth factor receptor.
    Higa GM
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1145-56. PubMed ID: 15606339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
    Venook AP
    Cancer; 2005 Jun; 103(12):2435-46. PubMed ID: 15880563
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.